Jefferies Gives a Buy Rating to Alcon (ALC)
Morgan Stanley Cuts STAAR to Underweight, Cites Growth Expectations
Alcon Analyst Ratings
Morgan Stanley Upgrades Alcon to Equalweight From Underweight, Raises Price Target to $85 From $65
Alcon Analyst Ratings
UBS Sticks to Its Buy Rating for Alcon (ALC)
Berenberg Raises Price Target on Alcon to CHF93 From CHF90, Cites Optimism for Second Half, Keeps Buy Rating
AlphaValue/Baader Europe Lowers Price Target on Alcon, Maintains Add Recommendation
UBS Sticks to Their Buy Rating for Alcon (ALC)
Kepler Capital Reaffirms Their Sell Rating on Alcon (ALC)
Alcon Analyst Ratings
Baird Adjusts Price Target on Alcon to $104 From $95, Maintains Outperform Rating
Analysts Offer Insights on Healthcare Companies: Alcon (ALC), ScPharmaceuticals (SCPH) and Ascendis Pharma (ASND)
Alcon Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Alcon (ALC), Annexon Biosciences (ANNX) and Ascendis Pharma (ASND)
Alcon Analyst Ratings
UBS Remains a Buy on Alcon (ALC)
Alcon Q1 2024: Strong Earnings Growth & Operational Efficiency Drive Buy Rating
Alcon's Solid Performance and Growth Momentum Justify Buy Rating Despite FX Headwinds
Alcon's Growth Trajectory: Positive Survey Insights and Product Launches Drive Buy Rating
No Data